Precision medicine enhances prostate cancer treatment with genetic profiling

Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy.

Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year – Biotech Investments

Xlife Sciences AG / Key word(s): IPO/Market launch 16-Dec-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

December 17, 2024

MDisrupt Secures $1M from American Heart Association Ventures

What You Should Know: – MDisrupt, a leading expert marketplace for the health tech and life sciences industries, has announced a significant milestone with a

October 16, 2024

NIH funding supports innovative lupus research using DNA mimic molecules

Lupus causes chronic pain, fatigue, and potentially organ damage for 1.5 million Americans and is a challenge for researchers trying to find better treatments.

December 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.